News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Universal Biosensors Release: LifeScan, Inc. Launch OneTouch® VerioTM IQ System in the United States


1/10/2012 9:47:56 AM

January 10, 2012 -- Universal Biosensors, Inc. (ASX: UBI) today announced that LifeScan, Inc. has launched the OneTouch® VerioTMIQ system in the United States. LifeScan’s press release in relation to the product is attached.

The launch represents a major milestone in the global roll-out of the OneTouch® VerioTM technology. The OneTouch Verio system is now available in all major self monitoring blood glucose (SMBG) markets including the United States, Canada, Europe and Australia. The continuing global roll-out further demonstrates LifeScan’s commitment to the OneTouch Verio technology.

The SMBG market in the US in 2010 was approximately US$3.84bn which represents approximately 40% of the global market. The US SMBG market is expected to grow to US$5.59bn by 2015.

LifeScan is the market leader in North America with approximately 33% of the SMBG market in 2008.

UBI CEO, Paul Wright said, “this is an extremely significant milestone in the development of UBI’s business and the commercialisation of its world-leading point of care diagnostics technology. The SMBG market in the US is the single largest diagnostics market in the world.”

UBI manufactures test strips for the OneTouch Verio system in its Rowville (Melbourne) facility.

Enquiries:

Mr Paul Wright: 03 9213 9000

About Universal Biosensors

For additional information in relation to Universal Biosensors, refer to http://www.universalbiosensors.com

Universal Biosensors is a specialist medical diagnostics company, founded in 2001, that is focused on the development, manufacture and commercialisation of a range of in vitro diagnostic tests for point-of-care use. These tests capitalise on a technology platform which uses a novel electrochemical cell that can be adapted for multiple analytes and provide for enhanced measurements in whole blood.

Forward-Looking Statements

The statements contained in this release that are not purely historical are forward-looking statements within the meaning of the Exchange Act. Forward-looking statements in this release include statements regarding our expectations, beliefs, hopes, intentions or strategies regarding the proposed offering. All forward-looking statements included in this release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations. We cannot assure you when, if at all, the proposed offering will occur, and the terms of any such offering are subject to change. Factors that could cause or contribute to such differences include, but are not limited to, factors and risks disclosed from time to time in reports filed with the SEC.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES